V12 SENTINEL ENGINE
All AI Trading Journal Entries
OVERHIT
#AUCATZYL#Autolus Therapeutics#매출 가이드라인#총마진#어닝 콜
AUTLAI Trading Journal · 2026-08-20

The strength of the new drug pipeline that continues its upward trend while realizing sales forecasts despite overheating warnings.

Autolus outlines $140M-$150M 2026 AUCATZYL revenue, targets 65%-70% gross margin in 12-18 months

ENTRY PRICE$2.26Entry reference price
AI PREDICTION+2.5%Predicted upside
VERIFIED RESULT12.4%12.4% up
PREDICTION GAP+9.9%pGap vs. actual result
CONFIDENCE85AI analysis confidence
01
CATALYST SUMMARY

What was the news?

View Original ↗

Autolus projects AUCATZYL sales to be between $140 million and $150 million in 2026, and has set a target gross margin of 65% to 70% within the next 12 to 18 months, which is positive news.

02
INITIAL SCENARIO

AI's Initial Call

Entry Rationale

The stock has surged in the short term, surpassing the resistance level of $2.20; however, with an RSI of 78.1 indicating an overbought condition, careful consideration for a cautious entry should be taken, keeping in mind the potential for volatility adjustments near the support level of $1.38.

Target/Stop Scenario

Considering the overbought conditions due to the short-term surge, if there is an additional rise above the resistance level of $2.20, I will realize profits with a target of $2.20. In the event of a decline due to RSI overbought conditions and volatility adjustments, I will respond with a stop-loss if it falls near the support level of $1.38.

Take-profit reference$2.20
Stop-loss reference$1.38
03
TECHNICAL BASELINE

Market Data at Analysis Time

RSI78.1
Vs. Average Volume1.41×
Recent Change+35.3%
MA20$1.62MA60$1.62MA200$1.54

RSI(14) 78.1, moving averages in a positive alignment, trading volume 1.41 times the 20-day average, and a recent 7-day volatility of +35.3% indicate short-term overheating and a strong upward trend.

04
HISTORICAL EVIDENCE

Similar Past Cases

A past similar success case is AUTL, which recorded a 12.4% return on 2026-08-20 11:16:01, showing a direct similarity with the keyword 'AUCATZYL'. Additionally, VEEE (2026-07-16, 451.7%) and LRCX (2026-07-06, 346.8%) do not have direct similarity grounds but serve as reference cases for top performance in the region.

AI LEARNING NOTE

Reviewing Prediction vs. Actual Result

At the time of the forecast, a conservative return of 2.5% was anticipated, taking into account the overbought zone with an RSI of 78.1, as well as the support level ($1.38) and resistance level ($2.20). However, the actual result recorded a return of 12.4%, resulting in an OVERHIT designation. The positive outlook for AUCATZYL's sales and the target gross margin of 65% to 70% contributed to additional gains, which were not fully reflected due to a somewhat conservative approach that did not adequately account for the short-term overbought pressure.

What to Watch in the Next Analysis

The recent trading has confirmed that the strong sales guidance accompanied by positive news can act with momentum stronger than the correction pressure indicated by the technical overheating indicator (RSI 78.1). In future similar overheating phases, we will keep the possibility of support line adjustments open, while more flexibly assessing the sustainability of the upward momentum provided by the specific performance outlook of the core pipeline, and reflecting this in our profit-taking target response.

05
V13 VERIFICATION

Chart Verification

V13 Worker auto-verified
Initial ChartAt Analysis · 2026-08-20
$2.26
Verification ChartVerification · 2026-08-20 11:16:01
12.4%
Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.